Welcome to our dedicated page for Processa Pharmaceuticals news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals stock.
Processa Pharmaceuticals, Inc. (PCSA) generates a steady flow of news as a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies and advancing select non-oncology programs. News coverage for PCSA commonly centers on its lead asset NGC-Cap (PCS6422 plus capecitabine) in advanced or metastatic breast cancer, where the company reports on Phase 2 trial enrollment milestones, interim analyses, and emerging safety and pharmacokinetic data.
Investors following PCSA news can expect detailed updates on clinical trial progress, including randomized Phase 2 study design features, preliminary findings on cancer-killing metabolite exposure, and comparative safety versus standard capecitabine monotherapy. Releases have highlighted how NGC-Cap may increase exposure to active metabolites while reducing toxic catabolites such as FBAL, along with observations on side-effect profiles like hand-foot syndrome.
Beyond oncology, Processa news also covers its rare disease and gastrointestinal programs, such as PCS499 in focal segmental glomerulosclerosis (FSGS) and PCS12852 for gastroparesis and related gastrointestinal motility disorders. Announcements have included acceptance of abstracts for major meetings like ASN Kidney Week and the signing of a binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852, with associated milestone, royalty, and equity terms.
PCSA news items frequently address capital markets and corporate strategy, including public offerings, private placements, reverse stock split approvals and implementation, and Nasdaq listing compliance updates. The company has also disclosed its evaluation of corporate cryptocurrency treasury strategies as part of its financial planning. In addition, Processa regularly announces participation in high-profile industry events such as the BIO International Convention, the American Society of Clinical Oncology (ASCO) Annual Meeting, and the J.P. Morgan Healthcare Conference, where management meets with investors and potential partners.
By monitoring this news feed, readers can track how Processa’s NGC platform, pipeline decisions, partnership activities, and financing events evolve over time, all based on the company’s own press releases and regulatory disclosures.
Processa Pharmaceuticals (Nasdaq: PCSA) has announced that Dr. David Young, Founder and President of Research & Development, will present at the World Orphan Drug Congress USA 2025 in Boston. The presentation, scheduled for April 24, 2025, at 2:00 p.m. ET, will focus on 'Applying Principles of FDA's Project Optimus to Oncology and Non-Oncology Rare Diseases'.
Dr. Young will discuss how Project Optimus principles can be utilized to determine optimal dosing for improved efficacy and safety in rare disease treatments, both oncological and non-oncological. This approach aligns with Processa's Regulatory Science strategy, which aims to enhance therapeutic outcomes through improved regulatory science methodologies.
Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage pharmaceutical company specializing in next-generation cancer therapies, has announced its participation in the upcoming MedInvest Biotech and Pharma Investor Conference. The event will take place on March 27-28, 2025, at Cooley's law office in New York City.
The company's management team will deliver a corporate overview presentation on March 28th at 9:40 a.m. Eastern time. Additionally, they will engage in one-on-one meetings with registered investors and conference attendees throughout the event. The presentation materials will be made accessible on Processa's website.
Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, has announced its participation in the 2025 BIO CEO & Investor Conference. The event will take place on February 10-11, 2025, at the New York Marriott Marquis.
The company's management will deliver a corporate overview presentation on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room. Throughout the conference, management will be available for one-on-one meetings with registered investors and attendees. Interested parties can schedule meetings through the BIO Partnering portal, while those unable to attend can contact Yvonne Briggs at Alliance Advisors to arrange meetings with management.
Processa Pharmaceuticals (PCSA) has completed its previously announced public offering, raising $5 million in gross proceeds. The offering included 8,050,672 shares of common stock (or pre-funded warrants) with accompanying Series A warrants to purchase up to 8,050,672 shares and Series B warrants for up to 4,025,336 shares.
The offering price was set at $0.615 per share for institutional investors and $0.7975 for the Company's CEO and board members. Notable participants included the Company's CEO, board members, existing institutional investors, and a healthcare-focused institutional investor. A.G.P./Alliance Global Partners served as the sole placement agent for the offering, which was conducted under a Form S-1 registration statement declared effective on January 27, 2025.
Processa Pharmaceuticals (PCSA) has announced the pricing of a $5 million public offering, featuring 8,050,672 shares of common stock with accompanying warrants. The offering includes participation from the company's CEO, board members, existing institutional investors, and a healthcare-focused institutional investor.
The offering is priced at $0.615 per share for institutional investors and $0.7975 for company insiders, with both Series A and Series B warrants included. Series A warrants allow purchase of up to 8,050,672 shares at $0.65 per share with a five-year term, while Series B warrants cover 4,025,336 shares at $0.65 per share with an eighteen-month term.
The closing is expected around January 29, 2025, with A.G.P./Alliance Global Partners acting as sole placement agent. The company must seek stockholder approval within 90 days for the issuance of shares upon warrant exercise.
Processa Pharmaceuticals reports progress in its oncology pipeline and Q3 2024 financial results. The company has dosed its first patient in a Phase 2 trial of NGC-Cap for metastatic breast cancer, with interim data expected in H2 2025. Preclinical studies for NGC-Iri showed improved tumor targeting compared to irinotecan and Onivyde®. Financial highlights include R&D expenses of $2.3M (up from $1.2M in Q3 2023), G&A expenses of $1.1M, and a net loss of $3.4M ($1.03 per share). Cash position stands at $2.9M as of September 30, 2024.
Processa Pharmaceuticals (Nasdaq: PCSA) has announced the dosing of the first patient in a Phase 2 clinical trial for NGC-Cap, targeting advanced or metastatic breast cancer. The trial (NCT06568692) is a global, multicenter, open-label study comparing two doses of NGC-Cap to FDA-approved monotherapy capecitabine in 60-90 patients.
Key points:
- The trial aims to evaluate NGC-Cap's safety-efficacy profile and determine optimal dosage regimens.
- Interim analysis results are expected in mid-2025.
- Three clinical trial sites have received approval, with plans to activate approximately 30 sites worldwide.
- Breast cancer is the second most common cancer globally, with over 2 million cases diagnosed in 2022.
- The five-year survival rate for metastatic breast cancer is approximately 30%.
Processa Pharmaceuticals (Nasdaq: PCSA) has announced its participation in two major conferences this September. The company will attend the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York. Management will conduct one-on-one investor meetings and deliver a company presentation, which will be available on-demand from September 9th at 7:00 am Eastern time on Processa's website.
Additionally, Processa will participate in the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona from September 13-17, 2024. During this event, management will meet with clinicians, researchers, industry key opinion leaders, and potential partners. These conferences provide Processa with valuable opportunities to showcase their developments and network within the pharmaceutical and investment communities.
Processa Pharmaceuticals (Nasdaq: PCSA) provides updates on its product pipeline and financials for Q2 2024. Key highlights include:
1. NGC-Cap: Phase 2 trial initiated in metastatic breast cancer with initial data expected mid-2025. Phase 1b showed favorable safety and preliminary anti-tumor activity.
2. NGC-Gem: Evaluating potential in pancreatic and other cancers. FDA meeting planned for late 2024/early 2025.
3. NGC-Iri: Preclinical studies showed greater tumor accumulation of SN-38 compared to irinotecan and Onivyde®.
4. Q2 2024 financials: R&D expenses $1.7M, G&A expenses $1.4M, net loss $3.0M ($1.01/share). Cash position $5.6M as of June 30, 2024.
Processa Pharmaceuticals (Nasdaq: PCSA) announces positive preclinical data for NGC-Iri, a next-generation irinotecan prodrug. Studies in human melanoma xenograft mouse models show NGC-Iri delivers more cancer-killing SN-38 to tumors than FDA-approved treatments irinotecan and Onivyde®. Key findings include:
1. Higher tumor-to-muscle SN-38 ratio (200 for NGC-Iri vs <15 for others)
2. Greater tumor-to-plasma SN-38 ratio (10 for NGC-Iri vs <7 for others)
3. Lower muscle-to-plasma SN-38 ratio (<0.10 for NGC-Iri vs >0.4 for others)
These results suggest NGC-Iri may offer improved efficacy and fewer side effects compared to existing treatments. Processa is currently defining the regulatory path for NGC-Iri, including target patient population and cancer type for FDA presentation.